Clinical profile of hereditary angioedema from a tertiary care centre in India.


Journal

Indian journal of medical microbiology
ISSN: 1998-3646
Titre abrégé: Indian J Med Microbiol
Pays: United States
ID NLM: 8700903

Informations de publication

Date de publication:
Historique:
received: 19 10 2020
revised: 16 03 2021
accepted: 29 03 2021
pubmed: 4 5 2021
medline: 30 12 2021
entrez: 3 5 2021
Statut: ppublish

Résumé

Hereditary angioedema (HAE) is a clinical condition which could be fatal if not identified and managed appropriately. Knowledge of this condition is mostly confined to individual case reports and literature reviews in India. In this retrospective study we describe HAE cases which presented to a tertiary care centre in India over a period of three and half years. Clinical case records of forty-two HAE patients diagnosed based on clinical and laboratory features were accessed after due approval from the Ethics committee. C1 esterase inhibitor (C1 INH) and C4 levels were measured using nephelometry. All relevant data was entered into Microsoft EXCEL worksheet and analysed using simple statistical tools. Among the 42 patients diagnosed as having HAE, 37 had low C1INH levels and were diagnosed to have type 1 HAE. The remaining 5 had normal C1 INH levels and were considered probable HAE based on family history and response to HAE specific treatment. The median age of onset of symptoms was 15 years (range 5-49) and median age at diagnosis, 27.5 years (range 5-55). The median delay in diagnosis was 10 years (range 1-27 years). Family history of HAE was observed in 52.6% and 29% reported deaths in the family with HAE like disease. Low dose androgens or tranexamic acid or both were prescribed in 64.2% of the patients. Orofacial edema was the commonest clinical presentation (76%) followed by edema of the extremities (38%), GI tract symptoms (19%) and genital involvement (11.9%). Many cases of HAE may be going undetected in India. There is a need for clinical awareness and laboratory means to accurately identify and administer appropriate treatment.

Identifiants

pubmed: 33934932
pii: S0255-0857(21)00051-7
doi: 10.1016/j.ijmmb.2021.03.021
pii:
doi:

Substances chimiques

Complement C1 Inhibitor Protein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-512

Informations de copyright

Copyright © 2021 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest financial or otherwise.

Auteurs

Susmitha Perumalla (S)

Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.

Lydia Mathew (L)

Department of Dermatology, Christian Medical College, Vellore, Tamil Nadu, India.

John Mathew (J)

Department of Rheumatology, Christian Medical College, Vellore, Tamil Nadu, India.

P Naina (P)

Department of ENT, Christian Medical College, Vellore, Tamil Nadu, India.

A J Joseph (AJ)

Department of Gastroenterology, Christian Medical College, Vellore, Tamil Nadu, India.

John Antony Jude Prakash (JAJ)

Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India. Electronic address: prakjaj@cmcvellore.ac.in.

Dincy Peter (D)

Department of Dermatology, Christian Medical College, Vellore, Tamil Nadu, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH